SCHEMBL7872976

SCHEMBL7872976

C=CCCCCC[C@H](N)C(=O)OC

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
LMNA P02545 2/20 0.51
MAPT P10636 4/20 0.48
USP2 O75604 3/20 0.48
CYP3A4 P08684 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 1/20 0.48
RECQL P46063 1/20 0.42
ABCC4 O15439 1/20 0.40
ZDHHC7 Q9NXF8 1/20 0.39
DDAH1 O94760 1/20 0.38
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.36
LPAR2 Q9HBW0 1/20 0.36
LPAR3 Q9UBY5 1/20 0.36
P2RY10 O00398 1/20 0.35
GPR174 Q9BXC1 1/20 0.35
PLA2G2C Q5R387 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24298179 1.00 ALDH1A1 (0.51) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL1128635 1.00 ALDH1A1 (0.51) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL8053498 0.98 ALDH1A1 (0.49) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL13248790 0.93 ALDH1A1 (0.46) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL1271958 0.93 ALDH1A1 (0.46) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL18109641 0.85 ALDH1A1 (0.40) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL7274493 0.85 ALDH1A1 (0.40) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL15723449 0.85 ALDH1A1 (0.40) ALDH1A1LMNAMAPTUSP2CYP3A4
SCHEMBL27405457 0.85 ZDHHC7 (0.48) CYP3A4ZDHHC7DDAH1TSHR
SCHEMBL27405459 0.85 ZDHHC7 (0.48) CYP3A4ZDHHC7DDAH1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2023-12-05 US disclosed
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2023-12-05 US disclosed
WO-2019075259-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS CORNELL UNIVERSITY (US) 2019-04-18 WO disclosed
WO-2014081886-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. (US) 2014-05-30 WO disclosed
US-8048862-B2 Macrocyclic inhibitors of hepatitis C virus replication INTERMUNE, INC. (US) 2011-11-01 US disclosed
US-8048862-B2 Macrocyclic inhibitors of hepatitis C virus replication INTERMUNE, INC. (US) 2011-11-01 US disclosed
US-20110081315-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-04-07 US disclosed
US-20110081315-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-04-07 US disclosed
US-20110059047-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-03-10 US disclosed
US-20110059047-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2011-03-10 US disclosed
WO-2009142842-A9 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2010-11-25 WO disclosed
WO-2009142842-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-26 WO disclosed
US-20090269305-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-10-29 US disclosed
US-20090269305-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090269305-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 ALDH1A1 2635/4885LMNA 1725/4885MAPT 4553/4885
US-20110059047-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, ZC3HAV1 ALDH1A1 2635/4885LMNA 1725/4885MAPT 4553/4885
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors PSMB5, PSMB1, PSMB3 ALDH1A1 4081/4885LMNA 3755/4885MAPT 1702/4885
US-20110081315-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, EIF4A2 ALDH1A1 1769/4885LMNA 1625/4885MAPT 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.